Product Description
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Chile | Pakistan
Approved Indications: None
Known Adverse Events: None
Company: Universitaire Ziekenhuizen KU Leuven
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Obesity
Phase 3: Colorectal Cancer
Phase 1: Type 2 Diabetes|Obesity
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ChiCTR2300071590 | N/A |
Not yet recruiting |
Alcoholism |
2025-06-30 |
|
Pro00111134 | N/A |
Completed |
Spinal Dysraphism|Urinary Bladder, Neurogenic |
2024-04-18 |
|
DINE | N/A |
Completed |
Weight Loss|Acute Respiratory Distress Syndrome|Obesity|Communicable Diseases |
2022-10-26 |
|
MM-BP | N/A |
Completed |
Depressive Disorder |
2022-04-10 |